22:56 , Jun 28, 2019 |  BC Extra  |  Company News

CHMP knocks Evenity for osteoporosis, backs Giapreza for hypotension

EMA's CHMP issued a basket of opinions Friday, including a negative opinion for Amgen's osteoporosis drug Evenity, and a recommendation for La Jolla's hypotension therapy Giapreza. The agency recommended against approval of Evenity romosozumab-aqqg from...
19:53 , May 13, 2019 |  BC Extra  |  Company News

May 13 Company Quick Takes: PeptiDream/JCR, Grail, Lilly, Onconova/HanX, Regeneron

PeptiDream, JCR deal produces drug carriers for CNS delivery  The 2016 partnership between PeptiDream Inc. (Tokyo:4587) and JCR Pharmaceuticals Co. Ltd. (Tokyo:4552) has led to the development of constrained peptides that bind TFRC and are...
18:05 , Mar 15, 2019 |  BC Week In Review  |  Clinical News

Lilly looks to expand Cyramza's label into first-line NSCLC

Eli Lilly said it plans to initiate global regulatory applications mid-year seeking to expand the label of Cyramza ramucirumab to include first-line treatment of metastatic non-small cell lung cancer in patients whose tumors have activating...
00:46 , Feb 1, 2019 |  BC Week In Review  |  Clinical News

Cyramza leads to median OS of 8.5 months in AFP-high HCC population

Eli Lilly and Co. (NYSE:LLY) reported additional data from the Phase III REACH-2 trial to treat hepatocellular carcinoma (HCC) in patients with high α fetoprotein (AFP) levels showing that second-line treatment with Cyramza ramucirumab led...
13:28 , Dec 4, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Clostridium Patient sample, cell culture and mouse studies suggest inhibiting VEGF-A, VEGFR-2 or HIF1 could help treat Clostridium difficile infection (CDI). In serum samples from patients, levels of VEGF-A were higher than in samples...
16:19 , Apr 27, 2018 |  BC Week In Review  |  Clinical News

Lilly's Cyramza misses OS endpoint in Phase III for urothelial carcinoma

Eli Lilly and Co. (NYSE:LLY) reported additional data from the Phase III RANGE trial in 530 patients with urothelial carcinoma showing that IV Cyramza ramucirumab plus docetaxel missed the secondary endpoint of improving overall survival...
21:06 , Apr 6, 2018 |  BioCentury  |  Finance

Smid-cap smorgasbord

While the biggest milestone of the second quarter came early and turned out to be a disappointment, investors still have plenty to look forward to in immuno-oncology. In addition, specialist investors’ current strategy of overweighting...
14:45 , Apr 6, 2018 |  BC Week In Review  |  Clinical News

Lilly's Cyramza meets in biomarker-selected HCC population

Eli Lilly and Co. (NYSE:LLY) said second-line treatment with Cyramza ramucirumab (IMC-1121B, LY3009806) met the primary endpoint of improving overall survival (OS) compared with placebo in the Phase III REACH-2 trial to treat hepatocellular carcinoma...
19:33 , Apr 4, 2018 |  BC Extra  |  Clinical News

Lilly's Cyramza meets in biomarker-selected HCC population

Eli Lilly and Co. (NYSE:LLY) said second-line treatment with Cyramza ramucirumab met the primary endpoint of improving overall survival (OS) compared with placebo in the Phase III REACH-2 trial to treat hepatocellular carcinoma in patients...
13:09 , Feb 16, 2018 |  BC Week In Review  |  Clinical News

Lilly reports detailed Phase III data for Cyramza in first-line gastric cancer

Eli Lilly and Co. (NYSE:LLY) reported additional data from the Phase III RAINFALL trial in 645 patients with HER2-negative metastatic gastric or gastroesophageal junction adenocarcinoma showing that IV Cyramza ramucirumab (IMC-1121B, LY3009806) plus cisplatin and...